ELOCTATE

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ELOCTATE
Generic name
ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC FUSION PROTEIN
Manufacturer
Bioverativ Therapeutics Inc.
Product type
PLASMA DERIVATIVE
SPL set ID
e1419c33-ef07-4268-be1f-c8993502d597
SPL ID
e600c559-32d8-4818-b600-141cc0d74cea
Version
10
Effective date
2023-05-05
Source export date
2026-11-13
Source partition
14
Source file
https://download.open.fda.gov/drug/label/drug-label-0014-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/087e7a9c7af51c6b12a0e8fd611a27cb8635e1910ad160b89995da9a4b39b1b3/drug-label-0014-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 18:18:22
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, immediately discontinue ELOCTATE and initiate appropriate treatment. ( 5.1 ) Neutralizing antibodies (inhibitors) to Factor VIII have been reported. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. ( 5.2 , 5.5 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions have been reported with ELOCTATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor VIII replacement products. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ELOCTATE. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected or if bleeding is not controlled after ELOCTATE administration, suspect the presence of an inhibitor (neutralizing antibody) [see Warnings and Precautions (5.5) ] . 5.3 Cardiovascular Risk Factors Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII. 5.4 Catheter-Related Complication If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteremia, and catheter-site thrombosis should be considered [see Adverse Reactions (6) ] . 5.5 Monitoring Laboratory Tests Monitor plasma Factor VIII activity by performing a validated test (e.g., one stage clotting assay), to confirm that adequate Factor VIII levels have been achieved and maintained [see Dosage and Administration (2) ] . Monitor for the development of Factor VIII inhibitors. Perform a Bethesda inhibitor assay if expected Factor VIII plasma levels are not attained, or if bleeding is not controlled with the expected dose of ELOCTATE. Use Bethesda Units (BU) to report inhibitor levels.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most frequently occurring adverse reactions (incidence >0.5% of subjects) reported in previously treated patients (PTPs) clinical trials were arthralgia, malaise, myalgia, headache, and rash. The most frequently occurring adverse reactions (incidence ≥1.0% of subjects) reported in previously untreated patients (PUPs) clinical trials were Factor VIII inhibition, device-related thrombosis, and rash papular. Previously Treated Patients (PTPs): The most frequently occurring adverse reactions (>0.5% of subjects) in clinical trials were arthralgia, malaise, myalgia, headache, and rash. ( 6 ) Previously Untreated Patients (PUPs): The most frequently occurring adverse reactions (incidence ≥1%) from clinical trial were Factor VIII inhibition, device-related thrombosis, and rash papular. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bioverativ Therapeutics Inc. at 1-855-693-5628 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. Previously Treated Patients (PTPs) ELOCTATE has been evaluated in 276 subjects in five completed studies in previously treated patients (PTPs) with severe Hemophilia A (<1% endogenous FVIII activity or a genetic mutation consistent with severe Hemophilia A) who received at least one dose of ELOCTATE as part of either routine prophylaxis, on-demand treatment of bleeding episodes or perioperative management. Sixty-nine (25.0%) were pediatric subjects <12 years of age, 25 (9.1%) were adolescents (12 to <18 years of age), and 182 (65.9%) were adults (18 years of age and older). There were 200 subjects treated for at least 104 weeks, 151 subjects treated for at least 156 weeks and 107 subjects treated for at least 208 weeks. The total number of exposure days (EDs) was 80,848 with a median of 294 (range 1-735) exposure days per subject. The subjects received a total of 82,024 injections with a median of 303.5 injections of ELOCTATE (range 1-755) per subject. Adverse events (AEs) were monitored for a total of 893.72 subject-years. Two subjects (0.7% of total 276) with cardiovascular risk factors each experienced a serious adverse reaction of myocardial infarction during the study. Adverse reactions (ARs) were reported for 11 of 276 (4.0%) subjects treated with routine prophylaxis or episodic (on-demand) therapy. No age-specific differences in ARs were observed between pediatric and adult subjects. Table 3 summarizes the most frequently occurring adverse reactions in PTPs. Additional adverse reactions, each occurring in a single subject (incidence 0.4%), include dizziness, dysgeusia, bradycardia, hypertension, hot flush, angiopathy (investigator term: vascular pain after injection of study drug), cough, lower abdominal pain, back pain, joint swelling, chest pain, feeling cold, feeling hot, and procedural hypotension. Two subjects were withdrawn from study due to adverse reactions of rash and arthralgia. In the studies, no inhibitors were detected and no events of anaphylaxis were reported. Table 3: Adverse Reactions Reported for ELOCTATE (N=276) in PTPs MedDRA MedDRA version 15.0 System Organ Class Adverse Reactions Number of Subjects n (%) Nervous system disorders Headache 2 (0.7) Skin and subcutaneous tissue disorders Rash 2 (0.7) Musculoskeletal and connective tissue disorders Arthralgia Myalgia 2 (0.7) 2 (0.7) General disorders and administration site conditions Malaise 2 (0.7) Previously Untreated Patients (PUPs) ELOCTATE safety was also evaluated in one completed study (PUPs study) in 103 subjects with severe hemophilia A (<1% endogenous FVIII activity). Overall, the median number of weeks on treatment was 64.24 weeks (range: 0.0–206.8 weeks). The number of subjects with at least 10 exposure days (EDs) was 87 (84.5%), at least 20 EDs was 85 (82.5%), and at least 50 EDs was 81 (78.6%). Adverse drug reactions (ADRs) were reported in 29 of 103 (28.2%) subjects treated with ELOCTATE on routine prophylaxis, episodic, and/or immune tolerance induction (ITI) therapies. ADRs in PUPs are summarized in Table 4 . Table 4: Adverse Drug Reactions Reported for ELOCTATE in PUPs Study MedDRA MedDRA version 22.0 System Organ Class Adverse Reactions Number of Subjects (%) N=103 The use of ELOCTATE for immune tolerance induction (ITI) was also investigated in 15 PUPs who had developed inhibitors (12 with high-titer inhibitors and 3 with low-titer inhibitors). Blood and lymphatic system disorders Factor VIII inhibition Two subjects who experienced events of factor VIII inhibition also experienced events of deep vein thrombosis in 1 subject and rash papular in another subject 28 (27.2) General disorders and administration site conditions Device related thrombosis Includes device-related thrombosis and deep vein thrombosis, each event occurred in 1 subject with an indwelling central venous catheter. 2 (1.9) Skin and subcutaneous tissues disorders Rash papular 1 (1.0) Immunogenicity Clinical trial subjects were monitored for neutralizing antibodies to Factor VIII. No PTPs developed confirmed neutralizing antibodies to Factor VIII. One 25 year old subject had a transient, positive, neutralizing antibody of 0.73 BU at week 14, which was not confirmed upon repeat testing 18 days later and thereafter. In PUPs Study, development of neutralizing antibodies (inhibitors) was observed in 28 subjects, 14 of them had a high-titer inhibitor. Based on subjects with an inhibitor test following an exposure day (ED) milestone or who developed an inhibitor at any time during the study, the incidence of Factor VIII inhibitor development was: 28/90 subjects (31.1%) with at least 10 EDs 28/86 subjects (32.6%) with at least 50 EDs The median time to inhibitor development for the 28 subjects was 9 EDs (interquartile range: 6.5–12). The detection of antibodies that are reactive to Factor VIII is highly dependent on many factors, including the sensitivity and specificity of the assay, sample handling, timing of sample collection, concomitant medications and underlying disease. Therefore, it may be misleading to compare of the incidence of antibodies to ELOCTATE with the incidence of antibodies to other products. 6.2 Postmarketing Experience The following adverse reactions have been identified during the postapproval use of ELOCTATE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Factor VIII inhibitor development Immune system disorders: hypersensitivity

adverse reactions table

<table ID="t3" width="100%"><caption>Table 3: Adverse Reactions Reported for ELOCTATE (N=276) in PTPs</caption><col width="35.900%" align="left"/><col width="41.067%" align="left"/><col width="23.033%" align="left"/><thead><tr><th align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">MedDRA<footnote>MedDRA version 15.0</footnote> System Organ Class</content></th><th align="center" valign="top" styleCode="Toprule Botrule Rrule"><content styleCode="bold">Adverse Reactions</content></th><th align="center" valign="top" styleCode="Toprule Botrule Rrule"><content styleCode="bold">Number of Subjects</content> <content styleCode="bold">n (%)</content></th></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Nervous system disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Headache</td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Skin and subcutaneous tissue disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Rash</td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Musculoskeletal and connective tissue disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Arthralgia Myalgia</td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.7) 2 (0.7)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">General disorders and administration site conditions</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Malaise </td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.7) </td></tr></tbody></table>

adverse reactions table

<table ID="t4" width="100%"><caption>Table 4: Adverse Drug Reactions Reported for ELOCTATE in PUPs Study</caption><col width="40%" align="left" valign="middle"/><col width="30%" align="left" valign="middle"/><col width="30%" align="center" valign="middle"/><thead><tr><th styleCode="Lrule Rrule">MedDRA<footnote>MedDRA version 22.0</footnote> System Organ Class</th><th styleCode="Rrule">Adverse Reactions</th><th styleCode="Rrule">Number of Subjects (%) N=103<footnote>The use of ELOCTATE for immune tolerance induction (ITI) was also investigated in 15 PUPs who had developed inhibitors (12 with high-titer inhibitors and 3 with low-titer inhibitors).</footnote></th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Blood and lymphatic system disorders</td><td styleCode="Rrule">Factor VIII inhibition<footnote>Two subjects who experienced events of factor VIII inhibition also experienced events of deep vein thrombosis in 1 subject and rash papular in another subject </footnote></td><td styleCode="Rrule">28 (27.2)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">General disorders and administration site conditions</td><td styleCode="Rrule" valign="top">Device related thrombosis<footnote>Includes device-related thrombosis and deep vein thrombosis, each event occurred in 1 subject with an indwelling central venous catheter.</footnote></td><td styleCode="Rrule" valign="top">2 (1.9)</td></tr><tr><td styleCode="Lrule Rrule">Skin and subcutaneous tissues disorders</td><td styleCode="Rrule">Rash papular</td><td styleCode="Rrule">1 (1.0)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.